MEMP Magazine July 2018
Cancer in Egypt: A special report written by Aalaa Abdou, a Clinical Oncology Specialist in Ministry of Health of Egypt. Page 38.
- Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H (2014) Cancer incidence in egypt: results of the national population-based cancer registry program. J Cancer Epidemiol2014: 437971.
- WHO Cancer country profiles 2014
- Ministry of health and population, Specialised Medical Centre web site http://smceg.com
- Hajdu, Steven I. (alone or with co-authors) “A Note From History: Landmarks in History of Cancer, Part 1~6.” Cancer, v. 117/5, 117/12, v.118/4, v. 118/8, 118/20 & 119/23 (2011-2013).
- Zheng YL, Amr S, Saleh D, Dash C, Ezzat S, Mikhail NN, et al. Urinary bladder cancer risk factors in Egypt: a multi-center case-control study. Cancer Epidemiol Biomarkers Prev. 2012;21:537–46.
- El-Akel W, El-Sayed MH, El Kassas M, et al. National treatment programme of hepatitis C in Egypt: hepatitis C virus model of care. J Viral Hepat. 2017;24(4):262–267.
Atavistic Chemotherapy: Breaking away from expensive and ineffective cancer drugs, written by Dr Frank Arguello, MD Director of Atavistic Chemotherapy Clinical Trial. Page 44.
- Ward, E., “Childhood and Adolescent Cancer Statistics,” CA Cancer J Clin., 64/2 (2014), 83–103
- “WHO EMRO | Cancer | Health Topics,” Emro.who.int, 2018 <http://www.emro.who.int/health-topics/cancer/index.html> [accessed 8 June 2018]
- Fojo, T., et.al., “Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity,” JAMA Otolaryngology–Head & Neck Surgery. 140/12 (2014), 1225
- Morgan, G., et.al., “The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies,” Clin Oncol. 16/5 (2004), 49-60
- Workman, P., et.al., “How Much Longer Will We Put Up With $100,000 Cancer Drugs?” Cell. 168/4 (2017), 579-583
- Prigerson, HG., et.al., “Chemotherapy Use, Performance Status, and Quality of Life at the End of Life,” JAMA Oncol. 1/6 (2015), 778-84
- Mann, D., “Majority of Advanced Cancer Patients Believe Chemotherapy Can Cure Them,” WebMD <https://www.webmd.com/cancer/news/20121024/incurable-cancer-patients-think-cure#1> [accessed 8 June 2018]
- Twombly, R., “Cancer surpasses heart disease as leading cause of death for all but the very elderly,” J Natl Cancer Inst. 97/330 (2005)
- Bailar, J.C., 3rd, Gornik, H.L. “Cancer undefeated,” N Eng J Med. 336/22 (1997), 1569-74
- Karagiannis G., et.al., “Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism,” Sci Transl Med. 9/399 (2017)
- Sun Y., et.al., “Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B,” Nat Med. 18/9 (2012), 1359-1368
- “Top 10 Oncology Pharmaceutical Companies 2017” <https://www.igeahub.com/2017/08/14/top-10-oncology-pharmaceutical-companies-2017/> [accessed 8 June 2018]
- “Global Cancer Drugs Market Size & Share Will Grow USD 161.30 Billion by 2021: Zion Market Research” <https://globenewswire.com/news-release/2017/07/03/1037328/0/en/Global-Cancer-Drugs-Market-Size-Share-Will-Grow-USD-161-30-Billion-by-2021-Zion-Market-Research.html> [accessed 8 June 2018]
- Arguello, F., “Atavistic Metamorphosis: a New and Logical Explanation for the Origin and Biological Nature of Cancer,” Charleston: CreateSpace Publisher 1 (2011)
- Nazaryan, A, “Getting Cancer Wrong: You Cannot Cure What You Do Not Understand,” 2014 <http://www.newsweek.com/2014/03/28/getting-cancer-wrong-248029.html> [accessed 8 June 2018]
- Snow HL. A treatise, practical and theoretic, on cancers and the cancer-process. London: Churchill; 1893
Compounding tablets in the Middle East: Benefits of small-scale tablet manufacturing systems written by Dr Michael Gamlen. Page 50.
- S Department of Health and Human Services. Food and Drug Administration. Human Drug Compounding. [FDA website.] Available at www.fda.gov Accessed 11.06.18
- Professional Compounding Centers of America. Compounding resources for patients. [PCCA website]. Available at pccarx.com Accessed 11.06.18
- American Pharmacists Association. Compounding resources for your practice. [APhA website]. Available at pharmacist.com Accessed 11.06.18
- ALLEN L. The Art, Science, and Technology of Pharmaceutical Compounding. 5th ed. American Pharmacists Association. 2016
- S. Pharmacopeia Convention. Compounding. [USP website]. Available at www.usp.org/compounding Accessed 11.06.18.
- Pellagatti T. Warfarin personalized dosage: Re-compounding for a more suitable therapy and better compliance. Int J Pharm Compd 2017 May-Jun;21(3): 247-250.
- United Nations. World Population Prospects. [United Nations website]. Available at un.org. Accessed 11.06.18
- The World Factbook. The World Factbook. [CIA website]. Available at cia.gov. Accessed 11.06.18
- GM Insights: Compounding Pharmacies Market 2018 – 2024 Report: May 2018. Available at gminsights.com Accessed 11.06.18
Non-alcoholic fatty liver disease: Does genetics have a role? Written by Dr Ravi Kanth. Page 62.
- Sharma M, Mitnala S, Vishnubhotla RK, Mukherjee R, Reddy DN, Rao PN. The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis. J Clin Exp Hepatol 2015; 5: 147-158.
- Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for Oncologist 2010; 15 Suppl 4: 14-22.
- Younossi Z, Anstee QM, Marietti M et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11-20.
- Loomba R, Schork N2, Chen CH et al. Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study. Gastroenterology. 2015;149(7):1784-93.
- Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461-5.
- Kozlitina J, Smagris E, Stender S, et al. Exomewide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014;46: 352-356.
- Holmen OL, Zhang H, Fan Y, et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat Genet 2014; 46: 345-351.
- Mahdessian H, Taxiarchis A, Popov S et al. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc Natl Acad Sci USA 2014; 111: 8913-8918.
NAFLD – Non alcoholic fatty liver disease; NASH – Non alcoholic steato hepatitis; HCC – hepatocellular carcinoma; USA – United states of America; IRS-1 – Insulin Receptor Substrate 1; ENPP1 – Ectonucleotide Pyrophosphatase/Phosphodiesterase 1; GCKR – Glucokinase regulatory protein; PPARG – peroxisome proliferator-activated receptor; TCF7L2 – Transcription Factor 7 Like 2; SLC2A1 – Solute Carrier Family 2 Member 1; SLC27A5 – Solute Carrier Family 27 Member 5; LIPN1 – Lipin 1; MTTP – Microsomal Triglyceride Transfer Protein; PEMT – Phosphatidylethanolamine N-Methyltransferase; ADIPOQ – Adiponectin; APOC3 – Apolipoprotein C3; APOE3 – Apolipoprotein E; NR1/2 (PXR) – Nuclear Receptor Subfamily 1 Group I Member 2; PPARA – Peroxisome Proliferator Activated Receptor alpha; FADS1 – Fatty Acid Desaturase 1; HFE – Hemochromatosis; SOD2 – Superoxide Dismutase 2; GCLC – Glutamate-Cysteine Ligase Catalytic Subunit; MRP2 (ABCC2) – Multidrug resistance-associated protein 2; MTHFR – methylenetetrahydrofolate reductase; TNF – tumor necrosis factor; sTNFr-2 – Tumor necrosis factor receptor 2; FDFT1 – Farnesyl-Diphosphate Farnesyltransferase 1; IL6 – Interleukin 6; AGT – Angiotensinogen; ATGR1 – Angiotensin II Receptor Type 1; KLF6 – Kruppel Like Factor 6; TGFb1 – Transforming Growth Factor Beta 1; COL13A1 – Collagen Type XIII Alpha 1 Chain; CDKN1A – Cyclin Dependent Kinase Inhibitor 1A; PNPLA3 – Patatin Like Phospholipase Domain Containing 3; TM6SF2 – Transmembrane 6 Superfamily Member 2